Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback